The occurrence of [[adverse drug reaction]]s (ADRs) with PDE5 inhibitors appears to be dose-related. [[Headache]] is a very common ADR, occurring in >10% of patients. Other common ADRs include: dizziness, flushing, [[dyspepsia]], nasal congestion or rhinitis.<ref name=Rossi/>

 


 
In 2007, the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) announced that a warning about possible [[Deafness|sudden hearing loss]] would be added to drug labels of PDE5 inhibitors.<ref name="FDA PDE5">{{cite web | url= http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109012.htm| title= FDA Announces Revisions to Labels for Cialis, Levitra and Viagra| author= | date= 2007-10-18| publisher= [[Food and Drug Administration]]| accessdate=2011-10-30 }}</ref>

 


 
Since 2007 there is evidence that PDE5 inhibitors can cause an anterior optic neuropathy.<ref name="Optic neuropathy">{{cite journal |doi=10.1111/j.1464-410X.2007.06839.x |title=The Phosphodiesterase Inhibitors and Non-Arteritic Anterior Ischaemic Optic Neuropathy: Increased Vigilance is Necessary |year=2007 |last1=Rao |first1=Amrith R. |last2=Thwaini |first2=Ali |last3=Ahmed |first3=Hashim U. |last4=Shergill |first4=Iqbal S. |last5=Minhas |first5=Suks |journal=BJU International |volume=100 |pages=3â€“4 |pmid=17488310 |issue=1}}</ref>

 


 
Other ADRs and their incidence vary with the agent and are listed in their individual pages.

 

